抄録
Denosumab is a fully human monoclonal anti - receptor activator for nuclear factor κB ligand (RANKL) antibody, which suppresses the differentiation, activation, and survival of osteoclasts by inhibiting the binding of RANKL to its receptor, RANK. In a phase Ⅲ clinical trial, denosumab significantly decreased the time-to-first and time-to-first-and-subsequent skeletal related events (SRE) in advanced cancer patients with bone metastases. One of the most important adverse reactions of denosumab is hypocalcaemia. So, we prepared a preset prescription formula that includes calcium lactate 4 g/day and alfacalcidol 0.25 μg/day so as to prevent hypocalcaemia, which might be caused by denosumab. We retrospectively examined the efficacy and safety induced by this preset formula on 35 patients who had advanced to bone metastases between the period of April 2012 and March 2013 at our medical center. In our preset formula patient group, no hypocalcaemia or hypercalcaemia symptoms were observed. We conclude that our formula (calcium lactate 4 g/day and alfacalcidol 0.25 μg/day) is safe and effective to prevent hypocalcaemia presumably caused by denosumab treatment.
